Document Detail

Endothelin in patients with chronic renal failure.
MedLine Citation:
PMID:  8570868     Owner:  NLM     Status:  MEDLINE    
Hypertension, anemia, and arteriovenous shunts represent very important pathogenic factors in the occurrence of cardiovascular morbidity and mortality in patients with chronic renal failure. It can be expected that endothelin (ET), the most potent vasoconstrictor known at present, can react in a significant way to the hemodynamic changes caused by the construction of a vascular shunt or anemia. In 14 patients the plasma ET concentration was examined before and 24 and 7 days after the construction of arteriovenous fistula. In 27 patients undergoing chronic hemodialysis treatment, ET was examined before the erythropoietin (EPO) therapy and after 2 months of EPO therapy, when partial correction of anemia had been achieved. The construction of arteriovenous fistula by itself had no significant influence on the plasma ET concentration. Subcutaneous application of EPO in doses that led to gradual correction of anemia was not accompanied by the rise of plasma ET. The average plasma concentration of ET was significantly higher in hemodialyzed patients, when compared to healthy controls as well as to patients with chronic renal failure before hemodialysis treatment was started.
K Nĕmecek; V Bártová; M Jáchymová; K Horký
Related Documents :
9040138 - Natural course of erosive arthropathy of the hand in patients undergoing hemodialysis.
9124748 - Pheochromocytoma, chronic renal insufficiency, and hemodialysis: a combination leading ...
10809418 - Body composition in hemodialysis patients--is it different from that of normal subjects?
7985668 - The association of intradialytic parenteral nutrition administration with survival in h...
19628938 - Progression of mild cognitive impairment to alzheimer's disease: improved diagnostic va...
16053398 - Low frequency of renal function impairment during one-year of therapy with tenofovir-co...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Renal failure     Volume:  17     ISSN:  0886-022X     ISO Abbreviation:  Ren Fail     Publication Date:  1995 Sep 
Date Detail:
Created Date:  1996-03-01     Completed Date:  1996-03-01     Revised Date:  2008-05-21    
Medline Journal Info:
Nlm Unique ID:  8701128     Medline TA:  Ren Fail     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  559-63     Citation Subset:  IM    
IInd Department of Internal Medicine Charles University, Prague, Czech Republic.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anemia / blood,  complications,  drug therapy
Arteriovenous Shunt, Surgical
Endothelins / blood*
Erythropoietin / therapeutic use
Kidney Failure, Chronic / blood*,  complications,  therapy
Middle Aged
Renal Dialysis
Reg. No./Substance:
0/Endothelins; 11096-26-7/Erythropoietin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Concentrating capacity in ifosfamide-induced severe renal dysfunction.
Next Document:  HCV viremia in hemodialysis patients: detection by a DNA enzyme immunoassay for amplified HCV sequen...